AGOMELATINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17NO2
Molecular Weight	243.301
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1

InChI

InChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N

InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H17NO2
Molecular Weight	243.301
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf

Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. Agomelatine is indicated for the treatment of major depressive episodes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Melatonin receptor 1A 6 Target ID: CHEMBL1945 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Agonist 2752	0.1 nM [Ki]
Melatonin receptor 1B 6 Target ID: CHEMBL1946 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Agonist 2752	0.12 nM [Ki]
Serotonin 2c (5-HT2c) receptor 131 Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Antagonist 2849	6.2 null [pKi]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Antagonist 2849	6.6 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 179 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf	Primary		Approved 8583	VALDOXAN Approved Use Treatment of major depressive episodes. Launch Date 2009

C_max

Value	Dose	Analyte	Population
211.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
176.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
250.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
182.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
385.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
203.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
12.032 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3 ng/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
191 ng/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
283 ng/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.032 ng/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED
10.891 ng/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
261.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
236.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
288.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
223.48 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
459.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
403.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
12.795 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 ng × h/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
405 ng × h/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
539 ng × h/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.637 ng × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED
11.572 ng × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.813 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.9 h OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.3 h OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.4 h OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.813 h EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED
0.96 h EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/			AGOMELATINE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14567168/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/14567168/	Sources: https://pubmed.ncbi.nlm.nih.gov/14567168/
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9140018/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/9140018/	Sources: https://pubmed.ncbi.nlm.nih.gov/9140018/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438 substrate 1193	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 MRP2 499 MRP3 246 MRP4 290 BSEP 550 CYP2C19 2057	CYP1A2 1197 CYP2C19 1119 P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 24.0	inconclusive [IC50 15.4871 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 25.0	inconclusive [IC50 19.4971 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 23.0	yes [IC50 15.4871 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 27.0	yes [IC50 34.6713 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 19.0	yes [IC50 4.8975 uM]

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	major
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	minor
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 109.0

PubMed

Title	Date	PubMed
Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.	2010-01	18801825
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.	2009-07	19370342
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.	2009-06	19440080
Agomelatine improves symptoms of generalised anxiety disorder.	2009-05	19395613
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats.	2009-04	18706130
Pathophysiology of depression: role of sleep and the melatonergic system.	2009-02-28	19181389
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.	2009	19442180
Insomnia in patients with depression: some pathophysiological and treatment considerations.	2009	19374460
Melatonin and melatonergic drugs on sleep: possible mechanisms of action.	2009	19326288
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.	2009	19255935
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.	2009	19228178
Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity.	2009	19177164
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.	2009	18609422
Agomelatine treatment of major depressive disorder.	2008-12	19033480
Melatonin and its agonists: an update.	2008-10	18827285
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.	2008-10	18794654
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.	2008-09	18837872
Addressing circadian rhythm disturbances in depressed patients.	2008-09	18753278
Innovation translates into antidepressant effectiveness.	2008-09	18753277
Agomelatine, an innovative pharmacological response to unmet needs.	2008-09	18753276
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.	2008-09	18583104
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.	2008-06-24	18466899
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.	2008-06	18480691
Gateways to clinical trials.	2008-04	18597009
[New hypnotics: perspectives from sleep physiology].	2008-02-13	18265473
Cellular and molecular mechanisms in the long-term action of antidepressants.	2008	19170396
Effects of different antidepressant treatments on the core of depression.	2008	18979944
Core symptoms of major depressive disorder: relevance to diagnosis and treatment.	2008	18979940
Promising avenues of therapeutics for bipolar illness.	2008	18689289
Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders.	2008	18673165
Agomelatine: AGO 178, AGO178, S 20098.	2008	18457470
Melatonergic drugs in clinical practice.	2008	18368944
Agomelatine: a novel atypical antidepressant.	2007-12	18246859
A review of the efficacy and tolerability of agomelatine in the treatment of major depression.	2007-12	18042007
Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).	2007-12	17826314
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.	2007-11	18052566
The interaction between the internal clock and antidepressant efficacy.	2007-10	17917564
High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder.	2007-10	17917563
Evidence of agomelatine's antidepressant efficacy: the key points.	2007-10	17917562
[Pharmacotherapy of depression: recent developments].	2007-09-19	17939526
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.	2007-09	17845278
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.	2007-09	17690597
Agomelatine and its therapeutic potential in the depressed patient.	2007-08	19300571
Jet lag: therapeutic use of melatonin and possible application of melatonin analogs.	2007-06-19	18342269
Gateways to clinical trials.	2007-06	17805439
Gateways to clinical trials.	2007-05	17609744
New antidepressants or more of the same?	2007	19300581
Role of the melatonin system in the control of sleep: therapeutic implications.	2007	18020480
The phase shift hypothesis for the circadian component of winter depression.	2007	17969866
Hippocampal neurogenesis, depressive disorders, and antidepressant therapy.	2007	17641737

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 25 mg once daily taken orally at bedtime. After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime. Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of LFT monitoring.

Route of Administration: Oral

In Vitro Use Guide

hypothalamic suprachiasmatic nucleus firing rates were dose-dependently suppressed by 19.2-80.9% following perfusion of 0.04-0.32mM agomelatine (p<0.001, IC50=0.14mM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:15 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:15 GMT 2025`
Record UNII	137R1N49AD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AGOMELATINE

Official Name

English

THYMANAX

Preferred Name

English

AGOMELATINE [MI]

Common Name

English

VALDOXAN

Brand Name

English

S20098

Code

English

Agomelatine [WHO-DD]

Common Name

English

N-(2-(7-METHOXY-1-NAPHTHYL)ETHYL)ACETAMIDE

Systematic Name

English

AGOMELATINE [EMA EPAR]

Common Name

English

agomelatine [INN]

Common Name

English

AGOMELATINE [MART.]

Common Name

English

S-20098

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C66885